Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil
Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma ( Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil )
19 Jun 2026

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma

Dr Ying Huang - CEO, Legend Biotech
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma ( Dr Ying Huang - CEO, Legend Biotech )
19 Jun 2026

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

Prof Ashutosh Wechalekar - University College London Hospitals, London, UK
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )
19 Jun 2026

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )
19 Jun 2026

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2026

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )
18 Jun 2026

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )
18 Jun 2026

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )
18 Jun 2026

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )
18 Jun 2026

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Prof David Kuter - Harvard Medical School, Boston, USA
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )
18 Jun 2026

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026